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1. Introduction 
The respiratory environment is exposed to a variety of different pathogens and irritants 
from the environment. We breathe in about 10,000 liters of air per day. As such, the immune 
cells along the respiratory tract constantly come into contact with pathogens and potential 
immunogens within the air. Since development of inflammatory responses to all these 
stimuli could result in persistent host responses and inflammation that could eventually be 
damaging to the lungs, the responses to potential respiratory pathogens, antigens and 
irritants must be tightly regulated and in some cases tolerated. Ideally, inflammatory 
responses should only occur when other initial mechanisms of protection, e.g. mucus, 
mucociliary clearance and phagocytes, are insufficient. Thus, in addition to the ability to 
differentiate between self and foreign antigens, as is done throughout the rest of the body, 
respiratory immune responses must also have the capacity to differentiate between harmful 
and innocuous antigens.  
Regulatory mechanisms throughout the body have evolved to control these immune and 
inflammatory responses, normally allowing for an immune response strong enough to deal 
with dangerous pathogens, but not so aggressive as to result in harmful immunopathology. 
Strong suppression by these regulatory mechanisms has been implicated in the 
pathogenesis of cancer, while weak suppression has been suggested to contribute to 
autoimmunity. In the lungs, mechanisms have evolved to similarly modulate host 
responses. This includes surfactants and alveolar macrophages that dampen host immune 
responses. Lymphocyte populations can also regulate pulmonary immune responses. The 
lymphocyte population most commonly associated with regulation of host immune and 
inflammatory responses, including tolerance to innocuous antigens, is the regulatory T (Treg) 
cell. Although much research has been done in the role of Treg cells in the pathogenesis of 
asthma, relatively little work has been performed examining these mechanisms in the 
context of bacterial infections, but the limited studies demonstrate that they can have a 
significant impact on these diseases. In this article, we will first briefly review the immune 
environment of the lung and the Treg cells and their function. We then focus on some 
bacterial lung diseases and what is known about the impact of Treg cells. Specifically, we will 
examine the potential for Treg cells to have both positive and negative effects on disease 
progression, depending upon the pathogen. 
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2. The pulmonary immune environment 
The lung is exposed to a variety of different pathogens and irritants from the environment. 
It would be harmful to the host if immune and inflammatory responses were generated in 
response to these agents, as it could result in constant inflammation and tissue destruction. 
Therefore, immune responses must be tolerant of these organisms so as not to upset the 
equilibrium that exists in the mucosal environment (Sansonetti, 2011). This requires a 
delicate balance between Treg cells and proinflammatory cells (Sansonetti, 2011).  
Research suggests that the lung environment tends to preferentially mount T helper type 2 
responses (Th2), though this is not absolute (Constant et al., 2000). The type of immune 
response elicited during bacterial infection is somewhat dependent on the site of infection, 
and the size of the antigen dose (Constant et al., 2000; Morokata et al., 2000). In addition, the 
type of antigen encountered by toll-like receptor-expressing cells can also determine the 
nature of the resultant immune response (Pulendran, 2004; Wissinger et al., 2009). Toll-like 
receptors are traditionally associated with antigen presenting cells, such as dendritic cells, 
macrophages, and B cells, though toll-like receptor stimulation on T helper cells has also 
been demonstrated to play an important role (Kawai & S. Akira, 2011; Palusinska-Szysz & 
Janczarek, 2010; Wissinger et al., 2009).  
3. Regulatory T cells 
Treg cells are a heterogeneous T cell population thought to maintain immunologic balance 
and prevent or minimize tissue damaging immune responses (Fehervari & Sakaguchi, 
2004a; Fehervari & Sakaguchi, 2004b; Sakaguchi, 2000, 2002, 2003). Treg cells are a subset of 
CD4+ T cells that make up anywhere from 1-10% of all CD4+ cells in the thymus, blood, and 
lymph (McHugh & Shevach, 2002). Unlike traditional T helper (Th) cells, Treg cells act to 
suppress or dampen the immune response. While evidence indicates that other cell 
populations may also have suppressive capabilities, such as natural killer T cells, gamma-
delta () T cells, and CD8+ suppressor cells, classical Treg cells are by far the most highly 
studied, the best understood, and, as far as the current evidence indicates, the most 
important in controlling the body’s immune responses (Bach, 2003; Born et al., 2000; Oh et 
al., 2008; Wang & Alexander, 2009).  
Very early on, Treg cells were implicated in autoimmune disorders. A lack of Treg cells was 
thought to be at least related to the onset of autoimmunity, if not the principal cause of it 
(Ellner, 1981). To date, Treg cell numbers have been found to be either abnormally low or 
poorly functioning in patients suffering from diseases such as lupus, rheumatoid arthritis, 
and myasthenia gravis (Flores-Borja et al., 2008; Mudd et al., 2006; Wang et al., 2008). 
Laboratory experiments have shown that adoptive transfer of Treg cells into lab animals 
prone to type I diabetes results in improved prognosis and delay of disease onset 
(Sakaguchi et al., 2006). Overall, these cells inhibit a wide range of autoimmune and 
inflammatory reactions, such as gastritis, oophoritis, orchitis, thryoidititis, inflammatory 
bowel disease (IBD), and spontaneous autoimmune diabetes. 
However, in some situations, Treg cells may restrict the actions of the immune system too 
much. The presence of Treg cells has been suggested to contribute to the progression of 
cancer. Again, laboratory experiments have shown that depletion of Treg cells can result in 
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enhanced killing of tumor cells by the immune response (Nomura & Sakaguchi, 2005). 
Similarly, Treg cells were also shown to contribute to the persistence of Leishmania major 
infection (Belkaid, 2003; Mendez et al., 2004). It is thought that Treg cells suppress the 
protective immune responses against cancer and some pathogens, resulting in prolonged 
disease. Furthermore Treg cells can suppress the cytokine production and proliferation of 
conventional Th cells (Jonuleit et al., 2001; Thornton & Shevach, 1998), but the Treg cells’ 
effects on Th cell subsets are conflicting with some studies (Stassen et al., 2004) suggesting 
dampening of Th2 responses and others (Suto et al., 2001) indicating promotion of Th2 cell 
responses. As a result, Treg cells may in some circumstances promote immune responses 
with varied results. Thus, Treg cells can have both positive and negative impacts on host 
responses in disease, highlighting the potential dual nature of Treg cells. 
First studied in the 1970’s, Treg cells, known then as suppressor T cells, were identified based 
on their ability to suppress antigen-specific immune responses. At that time, it was very 
difficult to study Treg cells due to the lack of any known markers specific to the cell type. As 
a result, the existence of Treg cells remained a very controversial idea for a long time. In 1995, 
it was shown by Sakaguchi et al. that Treg cells constitutively express the interleukin (IL)-2 
receptor alpha chain, CD25, at a high level (Nomura & Sakaguchi, 2005). The expression of 
the IL-2 receptor chain which is normally associated with activated T cells was theorized to 
be due to the continued T cell receptor engagement of self-antigens by these Treg cells, 
resulting in a perpetually active state. Thus, the characterization of Treg cells as CD4+CD25hi 
cells became widely accepted. Still, it remained somewhat difficult to distinguish Treg cells 
from activated Th cells, which also can express CD25, albeit at lower levels. Recently, the 
association of the intracellular transcription factor forkhead P3 (FoxP3) with Treg cells has led 
to the most accurate characterization of these cells to date: CD4+CD25hiFoxP3+ (Hori et al., 
2003). CD4+CD25hiFoxP3+ Treg cells also have other distinguishing surface markers such as 
GITR, CTLA-4, CD103, CCR4, CD62L, and CD127lo; however, the evidence that these 
markers are useful to phenotype Treg cells has yet to be established (Bayer et al., 2008; Fu et 
al., 2004; Liu et al., 2006; Sather et al., 2007; Shimizu et al., 2002; Wing et al., 2008; Zhao et al., 
2008).  
The mechanisms through which Treg cells exert their suppressive effects throughout the host 
appear to be numerous, and are likely dependent on the same factors that affect the typical 
immune response, such as the antigen dose, the nature of the pathogen or allergen, and the 
route of entry. The most common mechanism observed in both in vitro and in vivo 
experiments is secretion of cytokines, particularly IL-10 and transforming growth factor 
(TGF)-┚ (Bluestone & A. K. Abbas, 2003; Vignali et al., 2008; von Boehmer, 2005). Both of 
these cytokines are associated with Th2 responses, and, as such, are at odds with the more 
common Th1 response. Therefore, secretion of these cytokines by Treg cells reduces or 
dampens Th1 inflammatory responses. However, these are not the only cytokines that have 
been associated with Treg cells. IL-35, a member of the IL-12 family of cytokines, has recently 
been shown to play a role in Treg cell-mediated suppression (Chaturvedi et al., 2011; Collison 
et al., 2007; Collison et al., 2010). IL-35 is thought to be secreted only by Treg cells, and, while 
it is known to have a potent anti-inflammatory effect, the mechanism through which it 
exerts this effect is still poorly understood (Chaturvedi et al., 2011; Collison et al., 2007; 
Collison et al., 2010). In addition, recent experiments have suggested that Treg cells may also 
be able to suppress Th2 immune responses through the secretion of interferon (IFN)-and 
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IL-17, though this is still being studied (Ayyoub et al., 2009; Beriou et al., 2009; Esposito et 
al., 2010; Fang et al., 2009; Voo et al., 2009).  
Recent research has also shown that Treg cells may be able to exert suppression through 
galectin-1, which may be secreted or membrane-bound (Garin et al., 2007; Shevach, 2009). 
Galectin-1 has been implicated in cell cycle arrest, inhibition of proinflammatory cytokines, 
and even apoptosis of responder cells, though the mechanism remains unclear (Garin et al., 
2007; Shevach, 2009). Blockade of galectin-1 has been shown to abrogate suppression in both 
human and murine suppressive assays (Garin et al., 2007; Shevach, 2009). 
Direct killing of responder cells has also been proposed as a mechanism through which Treg 
cells can suppress immune responses (Cao et al., 2007; Shevach, 2009). Treg cells have been 
shown to express perforin, granzyme A, and granzyme B under certain conditions (Cao et 
al., 2007; Shevach, 2009). Treg cells that express this phenotype have been implicated in 
cytolysis of natural killer cells, T cells, and B cells (Cao et al., 2007; Shevach, 2009). Fas-FasL 
interaction has also been observed as a suppressive mechanism of Treg cells (Gorbachev & 
Fairchild, 2010; Strauss et al., 2009). Specifically, stimulation through Fas-FasL coupling has 
been shown to result in apoptosis of B cells and CD8 T cells in humans (Janssens et al., 2003; 
Strauss et al., 2009). In addition, there is evidence suggesting that Treg cells can interfere with 
priming of dendritic cells through Fas-FasL interaction, though it is not clear whether or not 
this involves cytotoxicity (Gorbachev & Fairchild, 2010).  
Other mechanisms that involve Treg cell interference with antigen-presenting cells have also 
been observed. Treg cells constitutively express CTLA-4, which binds the costimulatory 
molecules CD80 and CD86 (Shevach, 2009). The role of CTLA-4 is not clear, but there are a 
number of theories as to how it may function. First, CTLA-4 engagement of CD80 and CD86 
may restrict the further expression of costimulatory molecules by antigen-presenting cells 
(Onishi et al., 2008). Second, CTLA-4 may actually signal antigen-presenting cells to 
downregulate the expression of CD80 and CD86 (Onishi et al., 2008; Shevach, 2009). Third, 
the binding of CTLA-4 may simply block CD80 and CD86 from interacting with other cells, 
thus preventing the delivery of costimulatory signals (Shevach, 2009).  
The expression of LAG-3, a homolog of CD4 that binds MHC class II (Liang et al., 2008), by 
Treg cells may also be a mechanism through which these cells exert their influences. LAG-3 
produced by Treg cells has been demonstrated to suppress the maturation of antigen-
presenting cells (Liang et al., 2008). Treg cell expression of CD39 and CD73 may also prevent 
activation of antigen-presenting cells (Deaglio et al., 2007). These two surface molecules 
function together to break down extracellular ATP, which is released in large concentrations 
from damaged cells (Deaglio et al., 2007). Antigen-presenting cells can sense this 
extracellular ATP and undergo maturation and activation (Deaglio et al., 2007; Shevach, 
2009). By breaking down this ATP, Treg cells may be able to prevent activation of these 
antigen-presenting cells (Deaglio et al., 2007). Other mechanisms have also been suggested, 
such as secretion of fibrinogen-like protein 2 (fgl2), which may also depress the function of 
antigen-presenting cells, or surface expression of neurolipin-1 (Nrp-1), which may increase 
the strength of Treg cell binding to antigen-presenting cells (Sarris et al., 2008; Shalev et al., 
2008).  
Finally, there is evidence to suggest that Treg cells can prevent the activation of other cells by 
selective uptake of IL-2 (Chen et al., 2011; de la Rosa et al., 2004; Pandiyan et al., 2007). 
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Without IL-2, responder cells may never become activated, or they may become anergic or 
undergo apoptosis in the absence of costimulatory IL-2 (Chen et al., 2011; de la Rosa et al., 
2004; Pandiyan et al., 2007). These potential mechanisms are summarized in Table 1. 
Within the respiratory environment, most Treg cell research has focused on the role of these 
cells in the suppression of asthma. Asthma is a chronic inflammatory disease that afflicts the 
airways, resulting in airway hyperreactivity and spontaneous airway obstruction (Lloyd &. 
Hawrylowicz, 2009). It currently affects an estimated 300 million people worldwide, most of 
whom control the symptoms with glucocorticoid treatment (Lloyd & Hawrylowicz, 2009). 
Asthma is generally associated with a Th2 response, involving release of inflammatory 
mediators by T cells, mast cells and eosinophils (Lloyd & Hawrylowicz, 2009; Ray et al., 2010).  
Treg cells have long been implicated in the control of asthma, though the mechanisms 
through which they accomplish this control are still being studied (Lloyd & Hawrylowicz, 
2009; McGuirk et al., 2010; Ray et al., 2010). Depletion of Treg cells in murine models of 
asthma has been shown to greatly exacerbate symptoms (Lewkowich et al., 2005). This has 
been connected to a decrease in the Th1-promoting cytokine IL-12 and a concurrent increase 
in the Th2-associated cytokine IL-13 (Lewkowich et al., 2005). In addition, adoptive transfer 
of Treg cells has been shown to prevent airway inflammation and hyperreactivity, or even to 
suppress symptoms when transferred after the onset of disease (Kearley et al., 2008).  
Importantly, humans with mutations that impair Treg cell function tend to have a higher 
incidence of asthma (Caudy et al., 2007; Lloyd & Hawrylowicz, 2009). Asthmatic children 
have been observed to have lower levels of Treg cells in their lungs as compared with non-
asthmatics (Hartl et al., 2007). Another study suggests that asthmatics have lower overall 
expression of FoxP3 compared to healthy donors (Lloyd & Hawrylowicz, 2009). 
Furthermore, glucocorticoid treatment has been shown to transiently increase Treg cell 
numbers in asthmatic patients (Ryanna et al., 2009). A number of strategies have been 
proposed to increase Treg cells in asthmatics, including isolation and in vitro expansion of Treg 
cells, followed by their transfer back into the host (Ryanna et al., 2009). However, this would 
be an expensive and lengthy process. Thus, other therapies designed to promote in vivo Treg 
cell expansion are currently being explored. 
Recently, Treg cells have also been shown to express toll-like receptors, and experiments 
have demonstrated that toll-like receptors have an impact on Treg cell function (Dai et al., 
2009; van Maren et al., 2008). However, depending on the type of toll-like receptor that is 
stimulated, Treg cell function may be either enhanced or depressed (Dai et al., 2009; van 
Maren et al., 2008). This suggests, of course, that Treg cells may have different responses to 
pathogens depending on the type of antigen encountered and the type of toll-like receptor 
signal that is received. Thus, the role of Treg cells in different bacterial infections may vary 
widely depending on the nature of the bacteria. As such, the effect of Treg cells in respiratory 
infections can be complex and difficult to predict. 
4. Bacterial Respiratory Pathogens 
4.1 Mycoplasma 
As an infectious disease, mycoplasmas are probably the most under recognized pathogens 
known today. Often misconceived as a common cross-contaminate (Homberger &  
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Associated Protein/s Potential Mechanism Target Cell
Interleukin-10, TGF- Interference with T helper 
type 1 development and with 
secretion of proinflammatory 
cytokines
T cells, B cells, antigen-
presenting cells (Bluestone & 
Abbas, 2003; Vignali et al., 
2008; von Boehmer, 2005) 
Interleukin-35 Unknown Unknown (Chaturvedi et al., 
2011; Collison et al., 2007; 
Collison et al., 2010) 
Interferon-, Interleukin-17 Interference with T helper 
type 2 responses
Unknown
Galectin-1 Cell cycle arrest, inhibition of 
proinflammatory cytokine 
secretion, apoptosis
T cells, B cells (Garin et al., 
2007; Shevach, 2009) 
Perforin, Granzyme A, 
Granzyme B 
Direct cytotoxicity T cells, B cells, NK cells (Cao 
et al., 2007; Shevach, 2009) 
Fas-FasL Direct cytotoxicity, 
interference with antigen 
priming (dendritic cells)
B cells, CD8 T cells, Dendritic 
cells (Gorbachev & Fairchild, 
2010; Strauss et al., 2009) 
CTLA-4 Inhibition of antigen-
presenting cell maturation, 
induced downregulation of 
CD80 and CD86 expression, 
blockade of CD80 and CD86
Antigen-presenting cells 
(Onishi et al., 2008; Shevach, 
2009) 
LAG-3 Inhibition of antigen-
presenting cell maturation
Antigen-presenting cells 
(Liang et al., 2008) 
CD39, CD73 Inhibition of antigen-
presenting cell activation 
through breakdown of 
extracellular ATP
Antigen-presenting cells 
(Deaglio et al., 2007; Shevach, 
2009) 
Fgl2 Inhibition of antigen-
presenting cells 
Antigen-presenting cells 
(Sarris et al., 2008; Shalev  
et al., 2008)
Nrp-1 Strengthening of interaction 
with antigen-presenting cells 
Antigen-presenting cells 
(Sarris et al., 2008; Shalev  
et al., 2008)
Interleukin-2 Uptake of exogenous 
interleukin-2, prevention of 
responder cell activation 
T cells, B cells, Antigen-
presenting cells (Chen et al., 
2011; de la Rosa et al., 2004; 
Pandiyan et al., 2007) 
Table 1. Mechanisms of Regulatory T Cell-Mediated Suppression 
Thomann, 1994), mycoplasmas are in fact the etiological agent of a wide range of diseases in 
both animals and humans (Krause & Taylor-Robinson, 1992; Simecka et al., 1992). Because of 
their small size, mycoplasmas were first believed to be of viral origin. First isolated in 1898, 
Mycoplasma mycoides subsp. mycoides, was reported as the agent of contagious bovine 
pleuropneumonia in cattle (Nocard & Roux, 1990). Since, Mycoplasma species have been 
isolated from almost every domestic and laboratory animal.  
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Mycoplasma is commonly found as a respiratory pathogen. For example, Mycoplasma 
pneumoniae, the most common Mycoplasma in humans, causes up to 30% of all cases of 
community-acquired pneumonia. One study detected M. pneumoniae in over half of children 
above the age of five. This would make Mycoplasma the single most common pathogen in 
humans. While most cases of Mycoplasma infection are not life threatening, some do require 
hospitalization (more than 100,000 people per year). Mycoplasmas have also been suggested 
to have a role in the exacerbation of chronic asthma and certain autoimmune conditions 
(Atkinson et al., 2008; Dobbs et al., 2010; Woolard et al., 2004).  
There exists an interesting interplay between Mycoplasma and the host immune response. 
Most of the information in this regard is due to studies using the natural murine pathogen 
Mycoplasma pulmonis, which causes acute and chronic diseases of the respiratory tract in rats 
and mice (Hardy et al., 2002). Several studies demonstrated that immune responses against 
mycoplasma can be immunopathologic, contributing to disease severity. However, immune 
responses are also important in restricting infection to the lungs, preventing dissemination 
to other sites. Severe combined immunodeficient mice (T and B cell deficient) and athymic 
mice (T cell-deficient) develop less severe pulmonary lesions due to M. pulmonis infection 
than similarly infected wild type mice (Evengard et al., 1994; Keystone et al., 1980). 
Adoptive transfer of lymphocytes into severe combined immunodeficient mice prior to M. 
pulmonis infection restored the level of mycoplasma disease (Cartner et al., 1998). 
Importantly, no difference in lung colony forming units was observed in these studies, 
providing further evidence that the development of disease is due to immunopathologic 
immune responses. Depletion of T cells from hamsters showed a similar reduction in lesions 
after infection with M. pneumoniae (Taylor et al., 1974). Studies utilizing M. pulmonis have 
shown that disease severity is directly related to Th cells. Depletion of these cells prior to 
infection led to significant decreases in disease severity, as measured by weight loss and 
lesion incidence (Jones et al., 2002). Since Th cell responses can be separated into Th1 or Th2 
lineages, further studies were performed using IFN--deficient mice and IL-4-deficient mice. 
Mice lacking IFN- (which preferentially mounted a Th2 cell response) developed more 
severe disease upon infection with Mycoplasma pulmonis at an early time point (Woolard et 
al., 2004). In contrast, mice lacking IL-4 (which preferentially mounted a Th1 cell response) 
did not demonstrate any exacerbation of disease (Woolard et al., 2004). Furthermore, 
immunization with mycoplasma antigen results in resistance to infection in IL-4-deficient 
mice, but not IFN- deficient mice (Bodhankar et al., 2010). Overall, these studies suggest 
that Th2 responses contribute to mycoplasma-associated immunopathology, while Th1 
responses promote resistance to infection. 
CD8+ cytotoxic T cells also play a role in mycoplasma disease, though their role may be 
regulatory in nature. When CD8+ T cells were depleted from mice prior to infection with M. 
pulmonis, disease severity increased (Jones et al., 2002). Similar results were observed in 
studies involving rats. F344 rats developed less severe disease after infection with M. 
pulmonis as compared to LEW rats (Davis & Cassell, 1982; Davis et al., 1982, 1985). This was 
connected to higher levels of CD8+ T cells in the lungs and draining lymph nodes of F344 
rats compared to LEW rats. This effect may be due to the secretion of IFN- by CD8+ T cells, 
which could dampen immunopathologic Th2 cell responses. 
Recent studies from our lab showed that Treg cells clearly control the severity of disease in 
mycoplasma respiratory infection. Depletion of Treg cells using anti-CD25 antibody prior to 
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infection with M. pulmonis resulted in significant increases in clinical disease severity. The 
Treg cell-depleted mice lost significantly more weight over the course of the study and 
displayed a significantly higher incidence of gross lung lesions. In addition, Treg cell-
depleted mice had more severe histological lung lesions, which included increased 
peribronchial infiltration of inflammatory cells, airway exudate, epithelial hyperplasia, and 
alveolitis. This effect was clearly related to a decrease in the level of Treg cells, as the anti-
CD25 antibody was shown to specifically deplete CD4+CD25+FoxP3+ cells without affecting 
other cell populations. Increased disease in Treg cell-depleted mice was also concurrent not 
only with increases in lung cell infiltration but also with increases in the levels of 
mycoplasma-specific serum antibodies. Significantly, depletion of Treg cells had no effect on 
mycoplasma numbers (Odeh & Simecka, in preparation). Thus, Treg cells dampen the 
severity of inflammatory disease due to mycoplasma respiratory infection most likely 
through regulation of immune responses, in an apparent attempt to limit damage within the 
lung, but Treg cell activity does not contribute to persistence of mycoplasma infections, in 
contrast to other studies such as those discussed above with Leishmania infection. 
The mechanisms of how Treg cells regulate the development of inflammatory lesions is under 
investigation, but our results suggest that it is a result of activities of a novel population of 
Treg cells. Our studies demonstrated that there was an increase in total cell numbers in the 
lung of infected mice after Treg cell depletion, with almost all populations being affected. 
Most interestingly, there was a preferential increase in the percentage of IL-13+ cells in the 
lower respiratory lymph nodes due to Treg cell depletion prior to infection, suggesting Treg 
cells suppressed Th2 cell responses and perhaps promoted Th1 cell responses. Interestingly, 
there were increases in Treg cells in lower respiratory tract lymph nodes during mycoplasma 
disease pathogenesis, but neither IL-10 nor TGF- production by these Treg cells in response 
to mycoplasma could be demonstrated. Further characterization found that these Treg cells 
included two subpopulations that expressed either intracellular IFN-┛ or IL-17, suggesting 
that mycoplasma-specific Treg cells may act through novel mechanisms. In fact, in vitro 
cultures containing Treg cells and Th cells from infected mice secreted significantly higher 
levels of IFN- and IL-17 when stimulated with mycoplasma antigen as compared to Th cells 
alone. These data provided evidence that Treg cells might stimulate the secretion of IFN- 
and IL-17 cytokines by Th cells. In support, depletion of Treg cells from infected mice led to a 
decrease in the in vivo secretion of IFN-┛ and IL-17 by T helper cells (Odeh & Simecka, in 
preparation). These data suggest that two unique populations of Treg cells, IFN-┛+ or IL-17+, 
develop in mycoplasma-infected mice, and that these novel populations of Treg cells 
participate in control of the disease. Furthermore, these data suggest that IFN-┛+ and IL-17+ 
Treg cells promote the secretion of these cytokines by Th cells. Thus, the activation of this 
unique population of Treg cells in mycoplasma infections may be beneficial, as the 
stimulation of IFN-┛ and IL-17 production by Th cells would suppress the development of 
immunopathologic Th2 cell responses.  
4.2 Mycobacterium 
Current estimates are that one-third of the world population is infected with Mycobacterium 
tuberculosis (Bloom & Small, 1998; Dai et al., 2009; Urdahl et al., 2011). M. tuberculosis is 
responsible for 1.7 million deaths worldwide each year, though most of these deaths occur 
in developing countries, and/or in immunocompromised individuals (Kwan & Ernst, 2011; 
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Lawn & Zumla, 2011). The pathogenesis of tuberculosis is interesting. The disease is 
characterized by the persistence of infection and the formation of granulomas by the host to 
prevent the spread of the infection. Upon initial exposure, mycobacteria are phagocytosed 
by alveolar macrophages (Redford et al., 2011). However, through mechanisms that involve 
altered production of reactive nitrogen intermediates and prevention of phagosome 
maturation, M. tuberculosis bacteria are able to survive within the host cells (Flynn & Chan, 
2003; Redford et al., 2011). The persistence of Mycobacteria leads to granuloma formation, 
which not only prevents spread of the infection, but also benefits the bacteria by masking 
them from the immune response (Flynn & Chan, 2003). This results in a latent infection that 
never progresses to symptomatic tuberculosis (Flynn & Chan, 2003). Studies have 
demonstrated that control of tuberculosis is dependent on IL-12 and Th1 cell responses 
(Altare et al., 1998; Newport et al., 2003; Redford et al., 2011; Urdahl et al., 2011). Th1 cell 
responses are critical in macrophage activation and the formation and maintenance of the 
granuloma (Saunders & Britton, 2007). Thus, like Mycoplasma and other infectious diseases, 
the host response to M. tuberculosis infection is critical in determining the extent of lesions 
and outcome of infection, and, in the case of M. tuberculosis, impairment of Th1 responses 
against the pathogen leads to spread of infection and more severe disease. 
A small percentage of infected individuals, for reasons that are still not well understood, 
will develop symptoms, which include fever, cough, chest pain, and night sweats (Bark et 
al., 2011; Redford et al., 2011), but this is likely linked to a breakdown in Th1 responses 
meant to isolate the infection. One of the common findings in individuals with symptomatic 
tuberculosis, either from primary exposure or from reactivation of latent infection, is a high 
concentration of IL-10 in the blood (Boussiotis et al., 2000; Redford et al., 2011). In support of 
a critical role for IL-10 production in the pathogenesis of tuberculosis, IL-10 production was 
associated with the reactivation of tuberculosis in a mouse model of this disease (Turner et 
al., 2002). IL-10 can dampen macrophage activation and help stimulate the development of 
Th2 cell responses and alternatively activated macrophages (Kahnert et al., 2006). Taken 
together, IL-10 production in patients with active tuberculosis likely impairs the 
development or maintenance of a Th1 proinflammatory response, leading to a breakdown of 
the granulomas that are critical in limiting the spread of infection and damage to the host.  
Since populations of Treg cells are often a source of IL-10, studies were performed examining 
the role of Treg cells in M. tuberculosis respiratory infection. Treg cells in mice were indeed 
found to proliferate in response to mycobacteria infection (Shafiani et al., 2010) and were 
observed to localize to sites of Th cell responses in the lungs (Kahnert et al., 2006). By 
adoptively transferring M. tuberculosis specific Treg cells, it was found that Treg cells delayed 
the infiltration of effector T cells into the lung environment, and led to higher bacterial 
counts in the lungs of recipient mice (Shafiani et al., 2010). This delay in cell infiltration due 
to Treg cells likely impaired host responses that effectively control mycobacteria infection, 
disrupting protective granuloma formation. In fact, depletion of Treg cells results in higher 
numbers of mycobacteria (Kahnert et al., 2006). Thus, the production of Treg cell responses in 
tuberculosis can impair host resistance to infection, and in fact, the overactivity of Treg cells 
could participate in the transition of quiescent forms of tuberculosis to active disease. This 
represents a case where the attempt of Treg cells to dampen inflammatory responses may 
actually have a negative effect on disease outcome. 
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4.3 Bordetella 
Bordetella pertussis is the bacterium responsible for whooping cough, a disease that can afflict 
all age groups, but which is especially predominant and dangerous in children (Dunne et 
al., 2009; Marzouqi et al., 2010). In addition to the cough itself, other symptoms can include 
fever, nausea, convulsions, pneumonia, and, in severe cases, encephalopathy (Marzouqi et 
al., 2010). Even with the use of pertussis vaccines, the incidence of Bordetella infections is 
very high, with 40-50 million cases reported worldwide each year (Marzouqi et al., 2010). Of 
these, 300,000-400,000 result in death, mostly in children living in developing countries 
(Marzouqi et al., 2010). This makes whooping cough the most common vaccine-preventable 
disease in the world (Marzouqi et al., 2010). 
Upon initial exposure, B. pertussis adheres to the mucosal epithelium along the respiratory 
tract (de Gouw et al., 2011). It can then form a protective biofilm that allows it to mask itself 
from immune cells (de Gouw et al., 2011). There is even evidence that certain strains of 
Bordetella can invade host cells, thus avoiding many host responses (de Gouw et al., 2011). 
To promote its longevity and survival within the host, B. pertussis produces a number of 
toxins and virulence factors (de Gouw et al., 2011). It is well established at this point that 
clearance of Bordetella from the host requires a Th1 response, mediated by IFN-┛ (de Gouw 
et al., 2011). Experiments with vaccines have shown that augmentation of the IFN-┛-
mediated Th1 cell response leads to increased clearance of Bordetella (Marzouqi et al., 2010). 
To interfere with this, Bordetella can induce the production of IL-10, and, most interestingly, 
can stimulate the proliferation of IL-10-producing Treg cells (de Gouw et al., 2011; Higgins et 
al., 2003). Treg cells and IL-10 production can then dampen the Th1 cell response against the 
pathogen, delaying clearance of the organism and increasing its chances of transmission to 
another host (de Gouw et al., 2011). In mice depleted of Treg cells, there was an increase in 
the infiltration of immune cells into the lung environment (Higgins et al., 2003). This 
corresponded with a significant increase in the incidence of lung lesions, indicating a strong 
inflammatory response against the infection (Higgins et al., 2003). Thus, it appears that B. 
pertussis harnesses the host’s own mechanisms to modulate inflammatory responses by 
stimulating Treg cells to dampen these responses, thus preventing efficient elimination of the 
pathogen. 
However, the role of Treg cells in Bordetella infections is more complex. The cascade of 
events through which B. pertussis stimulates Treg cell activity is mediated by toll-like 
receptors. Studies demonstrated that Bordetella infection results in the production of IL-10 
by dendritic cells (Higgins et al., 2003). The stimulation of dendritic cells to produce IL-10 is 
driven by engagement of toll-like receptor 4 (TLR4). The IL-10 released by Bordetella-
stimulated dendritic cells, in turn, helps to promote the expansion of the IL-10-secreting Treg 
cell population (Higgins et al., 2003). This is supported by studies showing that B. pertussis 
infection of TLR4-deficient mice results in a significantly lower number of antigen-specific 
Treg cells than is found in wild-type mice. Furthermore, there was a concurrent decrease in 
the IL-10 levels (Higgins et al., 2003). The absence of IL-10-secreting Treg cells resulted in an 
increase in the infiltration of immune cells into the lung environment (Higgins et al., 2003). 
This corresponded with a significant increase in the incidence of lung lesions, indicating a 
strong immunopathologic response (Higgins et al., 2003). Thus, B. pertussis utilizes a 
pathway mediated by TLR4 recognition of the organisms to stimulate Treg cell-mediated 
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suppression of inflammatory responses that prevents both efficient clearance of the 
organism and damaging immunopathologic responses. 
4.4 Chlamydia and streptococcus 
There has been little additional work done on the role of Treg cells in other types of 
respiratory infections. However, there are some interesting studies on Chlamydia and 
Streptococcus respiratory infections that suggest an important role for Treg cells in these 
diseases.  
Chlamydia muridarum is a murine pathogen that causes disease similar to that of Chlamydia 
trachomatis in humans (Carey et al., 2011). As such, it is commonly used as a murine model. 
Normally, C. trachomatis manifests in humans as a sexually-transmitted disease, infecting the 
genital tract (Carey et al., 2011). However, it can infect other sites as well, including the 
respiratory tract, and, as a result, experiments have been performed using experimental C. 
muridarum lung infections (He et al., 2011). TLR2-deficient mice infected intranasally with C. 
muridarum developed more severe lung inflammation and more severe overall disease as 
compared to chlamydia-infected wild type mice (He et al., 2011). This was associated with 
an increase in the concentrations of the profinflammatory cytokines IFN-┛, IL-12, and IL-17, 
and a concurrent increase in the infiltration of immune cells in lung tissue (He et al., 2011). 
However, the lack of TLR2 had no effect on the clearance of the organism, as no differences 
in bacterial counts were found between wild type mice and TLR2-deficient mice (He et al., 
2011). Recently, engagement of TLR2 was shown to promote the development of Treg cells 
(Chen et al., 2009). Thus, it has been theorized that the increased immunopathology in C. 
muridarum-infected, TLR2-deficient mice may be due to a deficiency of Treg cells, though this 
has not yet been conclusively demonstrated (He et al., 2011). If so, the TLR-mediated 
mechanisms involved in promoting Treg cell activity by C. muridarum infection may be 
similar to those described above for Bordetella, and this could be a common approach 
through which some bacteria harness the immunosuppressive activity of Treg cells. 
One of the most common respiratory bacteria, and the one most often responsible for severe 
cases of pneumonia, is Streptococcus pneumoniae (Jones et al., 2010). Despite its role as the 
quintessential pneumococcal pathogen, very little work has been performed in the area of S. 
pneumoniae and Treg cells. In studies that examined the role of Streptococcus in asthma and 
airway hyperreactivity, it was shown that both intact S. pneumoniae and pneumococcal 
proteins can induce the development of Treg cells (Preston et al., 2011; Thorburn et al., 2010). 
The role of Treg cells in pneumococcal disease is unclear, but recent studies have begun 
examining the role of Treg cells in the generation of humoral immune responses against S. 
pneumoniae. Mice were treated with Treg cell-depleting antibodies and infected with live 
streptococcus. These mice develop similar levels of antibody responses as those in normal 
mice with intact Treg cell activity (Lee et al., 2005). Similar results were obtained when mice 
were given heat-killed streptococcus or protein-polysaccharide conjugates (which are used 
in S. pneumoniae vaccines) (Lee et al., 2005). Thus, it appears that Treg cells do not play a role 
in the development of anti-streptococcal humoral immunity. Further studies are needed to 
determine whether Treg cells play a role in disease pathogenesis or modulating protective 
immunity against S. pneumoniae. However, the data do suggest that other bacterial species 
can promote the development of Treg cell responses, which may play variable levels of 
importance depending upon the bacteria, the host, and the infection. 
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5. Conclusion 
As discussed above, there has been limited work examining the role of Treg cells in the 
pathogenesis of bacterial lung diseases. It is clear that modulation of Treg cell activity is done 
in some cases to benefit the host and in other cases benefitting the pathogen. Because the 
lung is a critical organ and a common site for exposure to infection, Treg cell activity is 
probably most important in dampening inflammatory responses to infections in order to 
minimize damage to the lung tissue. As indicated earlier, there are multiple mechanisms 
through which Treg cells modulate these inflammatory responses and lesions. Although one 
of the most common mechanisms is through the production of the anti-inflammatory 
cytokine IL-10, Treg cells, as shown in Mycoplasma pneumonia, may also prevent the 
development of potentially damaging immune responses by promoting other types of 
immunity. Interestingly, some respiratory pathogens, as well as other bacteria, have devised 
mechanisms to promote Treg cell development in an apparent attempt to interfere with host 
resistance and delay their clearance. Thus, Treg cells likely have varied activities in 
pulmonary bacterial diseases, which are probably host and bacterial species specific. 
Research on Treg cells and bacterial infections may also benefit treatment of other respiratory 
diseases. In recent years, a large amount of research has examined the role of Treg cells in 
asthma and other allergic diseases. Specifically, research indicates that stimulating the 
development and activation of regulatory T cells may suppress allergic reactions and 
asthma (Ray et al., 2010). Suggested methods for how to stimulate the development of Treg 
cell responses vary. Interestingly, one possible approach involves treatment of patients with 
bacteria or bacterial products (Fonseca & Kline, 2009; Trujillo & Erb, 2003), and indeed, there 
are cases in which this type of therapy has been experimentally validated (Crother et al., 
2011; Preston et al., 2011; Thorburn et al., 2010). This promising approach may have a 
broader utility since, as discussed in this article, different kinds of bacteria appear to be able 
to elicit different types of Treg cell responses. This suggests that further studies into how 
bacteria activate Treg cells are merited and could result in novel approaches to selectively 
and appropriately activate Treg cells in the treatment of certain human diseases. 
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